Post by
DavidRosenberg on Feb 09, 2022 11:38am
Near term catalysts
FSD Pharma wants to sell their previous cannabis facility for $21M Canadian
$ELYM elium therapeutics has their PEA results due 1st half of 2022 it could be positive or negative catalyst towards FSD Pharma because FSD Also has PEA
FSD PEA needs a new indication for a phase 2 clinical trial in the works
If they can sell the cobourg facility they can use that to improve their balance sheet
Lucid Psych - their major depressive drug candidate which is psychoactive is not yet patented from what i understand
Lucid MS - is fully patented not only in USA but also in EU
Preclinical mouse models in auto immune multiple sclerosis has shown to restore the limbs of the mice.
Lucid MS needs to start IND and or phase 1 clinical trials
Thank you
Comment by
Mil_Man54 on Feb 09, 2022 11:56am
So nothing then...just ifs and maybes and hopefullies....I mean look at your first statement Rosenberg...I want to have the winning lottery ticket....your statement has no merit...in fact...my statement has a better chance of coming true that them selling that plant for $21M....you post fluff and no substance....and turn a blind eye to reality....pumper 101....